DRMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DRMA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical setup is neutral-to-weak, the company’s latest quarter shows deteriorating profitability, analyst targets were cut sharply due to dilution, and there are no meaningful bullish news or insider/catalyst signals. I would not buy this stock now; the clearer call is sell/avoid until fundamentals and trend improve.
The trend is weak and indecisive. Price closed at 1.26, below the pivot at 1.295 and under the prior close of 1.30, which shows short-term softness. RSI_6 at 52.1 is neutral, so there is no strong momentum. MACD histogram is slightly positive but contracting, which suggests upside momentum is fading rather than accelerating. Moving averages are converging, signaling a lack of clear trend direction. Support sits at 1.211 and 1.159, while resistance is 1.379 and 1.431. Overall, the chart does not show a strong buy setup, and the stock trend model also points to downside bias over the next day and month.
No recent news in the last week. AI Stock Picker: no signal on given stock today. SwingMax: no signal on given stock recently. There are no notable bullish insider or hedge fund accumulation trends, and no recent congress trading data available. The only mild positive is that the stock is still trading near support levels, which could allow a short-term bounce, but that is not enough to justify a buy for this investor profile.
Q4 financials were weak: revenue was flat at 0, net income fell to -1.86M, and EPS dropped sharply year over year. Analyst sentiment turned more cautious as Maxim cut its price target from $10 to $4, citing dilution, even while keeping a Buy rating. Hedge funds and insiders are both neutral, suggesting no strong conviction from informed holders. The stock trend model is bearish over the next week and month. No recent news means there is no fresh catalyst to re-rate the stock higher.
Latest quarter: 2025/Q4. Financial performance was poor, with revenue at 0 and no growth, net income declining 40.91% YoY to -1,861,888, and EPS worsening 91.99% YoY to -1.65. Gross margin was flat at 0. This indicates continued financial strain and no evidence of scalable operating improvement in the most recent quarter.
Recent analyst trend is negative on valuation expectations. On 2026-04-01, Maxim lowered its price target to $4 from $10 while keeping a Buy rating, but explicitly tied the reduction to share dilution and wider GAAP losses in Q4. Wall Street’s pros view is that the company still has speculative upside potential, but the cons view is stronger right now: dilution, weak earnings quality, and a sharply reduced target imply confidence has weakened.
